Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jul 17, 2022 7:49pm
244 Views
Post# 34830185

RE:RE:RE:13 July 2022 15$ US target maintained

RE:RE:RE:13 July 2022 15$ US target maintained My satisfied, happy, ecstatic?
don't really know?
The $15ps target includes very little extra developments. Only assumes a phase 3 partnership.
a total buy out, interesting has never been discussed by any analysts.
The present math indicates roughly $15ps/ billion of company value.
It was mentioned on another site, that the tax loss value for an acquiring company is in excess of $5ps.
Meaning a bargain fire sale would be in excess of $5 ps.
Add on the value of the A.N. Deal....assuming phase 3 gets started. Easy into mid teens/ share.
My " sell" will depend on many variables, some related to Onc , some my personal needs.
Assuming they go the partnership route. That would bring about a new level of interest & trading price not seen in a long time.
I would sell " some" to meet personal $$ goals.
A buy- out regardless of price would be in excess of $15 ps...how far in excess, depends on the science.
We have seen lessor junior bio bought out for more that $ 1 billion.
Satisfied ? Any deal that moves Pela forward....I'd also be happy.
extatic ?  Anything over $3 billion would be IMHO a reasonable deal....$ that would be $45ps.


<< Previous
Bullboard Posts
Next >>